NCCN Guidelines Version 1.2025
- Active (symptomatic) Myeloma
- Multiple Myeloma
- Smoldering (asymptomatic) Myeloma
- Solitary Plasmacytoma
Multiple Myeloma-English Version 2025
Multiple Myeloma-Chinese Version 2023
Multiple Myeloma-French Version 2023
Multiple Myeloma-Korean Version 2022
Multiple Myeloma-Spanish Version 2025
Continuing Education
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
Management of Multiple Myeloma: Smoldering, Newly Diagnosed, and Relapsed/Refractory Disease
Managing Post-Treatment Complications for Multiple Myeloma and Acute Lymphocytic Leukemia
Translations
Arabic Version 5.2022
Chinese Version 2.2024
French Version 5.2022
German Version 5.2022
Italian Version 5.2022
Japanese Version 5.2022
Korean Version 5.2022
Polish Version 1.2023
Portuguese (Latin America) Version 3.2023
Romanian Version 1.2023
Russian Version 1.2023
Spanish (European Editions) Version 5.2022
Spanish (Latin America) Version 3.2023
Ukrainian Version 3.2023
Harmonized
English (Africa) Version 1.2025